Clinical Trials Browser

Phase 2 × Nasopharyngeal Neoplasms × Immunotherapy × Clear all

NCT06811844 2025-07-01

Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC

Phase 2 Recruiting

Pathologic Complete Response, Nasopharyngeal Neoplasms